11/21
08:48 am
xbio
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis [Yahoo! Finance]
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis [Yahoo! Finance]
11/21
08:30 am
xbio
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
11/13
08:30 am
xbio
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
High
Report
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
11/12
09:00 am
xbio
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
11/7
09:00 am
xbio
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Low
Report
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
10/22
09:21 am
xbio
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 [Yahoo! Finance]
Medium
Report
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 [Yahoo! Finance]
10/22
08:45 am
xbio
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Low
Report
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
10/17
09:02 am
xbio
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform [Yahoo! Finance]
10/17
08:30 am
xbio
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Medium
Report
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
9/11
09:00 am
xbio
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference